09:20 AM EDT, 06/20/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday the phase 3 trial of Tremfya subcutaneous induction therapy in adults with Crohn's disease reached both co-primary endpoints.

The trial achieved "statistically significant and clinically meaningful outcomes for clinical remission at week 12 as well as endoscopic response at week 12," the company said.

All secondary endpoints at weeks 12, 24 and 48 were also "statistically significant" compared with placebo, it said.

Results from the trial will be presented at medical meetings and will be shared with regulators, the company said.

Price: 145.28, Change: -0.37, Percent Change: -0.25